Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of renal impairment on pharmacodynamics and pharmacokinetics of RO4998452: A multiple-center, open-label, parallel group study following single oral dosing of RO4998452 to Type 2 Diabetes patients with varying degrees of renal impairment.

Next Previous
Search
Trial Profile

Effect of renal impairment on pharmacodynamics and pharmacokinetics of RO4998452: A multiple-center, open-label, parallel group study following single oral dosing of RO4998452 to Type 2 Diabetes patients with varying degrees of renal impairment.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Dec 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche

    • Most Recent Events

    • 15 Sep 2010 Status changed from active, no longer recruiting to completed as reported by Roche.
    • 25 Mar 2010 Status changed from recruiting to active, no longer recruiting as reported by Roche record.
    • 18 Feb 2010 Planned number of patients changed from 32 to 36 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top